2018

1. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1470-1486

2. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566

3. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545

4. Clinical utility of FDG-PET for the clinical diagnosis in MCI

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508

5. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1509-1525

6. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1546-1556

7. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1487-1496

8. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1526-1533